出处
《中国实用外科杂志》
CSCD
北大核心
2007年第3期192-194,共3页
Chinese Journal of Practical Surgery
参考文献12
1 Malchow H,Ewe K,Brandes JW,et al.European cooperative Crohn's disease study(ECCDS):results of drug treatment[J].Gastroenterology,1984,869(2):249-266.
2 Summers RW,Switz DM,Sessions JT Jr,et al.National cooperative Crohn's disease study:results ofdrug treatment[J].Gastroenterology,1979,77(4):847-869.
3 Rutgeerts P,Geboes K,Vantrappen G,et al.Predictability of the postoperative course of Crohn's disease[J].Gastroenterology,1990,99(4):956-963.
4 Borley NR,Mortensen NJ,Jewell DP.Preventing postoperative recurrence of Crohn's disease[J].Br J Surg,1997,84(11):1493-1502.
5 Brignola C,Lannone P,Pasquali S,et al.Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease[J].Dig Dis Sci,1992,37(1):29-32.
6 Vollaard EJ,Clasener HA.Colonization resistance antimicrob[J].Agents Chemother,1994,38(4):409-414.
7 Elmer GW,Surawice CM,McFarland LV.Biotherapeutic agents[J].JAMA,1996,275(11):870-876.
8 Duggan C,Gannon J,Walker WA.Protective nutrients and functional foods for the gastrointestinal tract[J].Am J Clin Nutr,2002,75(5):789-808.
9 van Staa TP,Card T,Logan RF,et al.5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease:a large epidemiological study[J].Gut,2005,54(11):1573-1578.
10 Ardizzone S,Maconi G,Sampietro GM,et al.Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease[J].Gastroenterology,2004,127(3):730-740.
1 松枝启,盛利纯.炎症性肠疾病的营养疗法[J] .日本医学介绍,1989,10(10):437-438.
2 郭海建.细胞因子与炎症性肠病[J] .医学新知,1996,6(2):85-89.
3 刘静芳.炎症性肠病肠外表现浅析[J] .河南诊断与治疗杂志,1998,12(2):77-77.
4 马进.炎症性肠疾病合并癌症[J] .日本医学介绍,1989,10(7):311-312.
5 马场裕子,姚桢.炎症性肠疾病的诊疗与进展[J] .日本医学介绍,1997,18(12):543-546.
6 郑里,王淑仙,崔德玉,崔艳英.介绍一种简便的炎症性肠疾病的评价方法[J] .中国药理学通报,1996,12(5):468-469. 被引量：29
7 阳惠湘,林敏娟,陈爱莲.克隆病20例临床分析[J] .湖南医科大学学报,2001,26(5):490-490. 被引量：2
8 刘凤林,秦新裕.炎症性肠疾病的诊断及鉴别诊断[J] .中国实用外科杂志,2007,27(3):189-191. 被引量：4
9 李雁.老年糖尿病临床治疗及预防[J] .中国现代药物应用,2013,7(24):84-85.
10 王云,李冬梅,王金芝,杨霖芝.糖尿病的社区健康教育[J] .中国医药指南,2010,8(31):172-173.
